Evidence map›Paper›PMID 34129819›Full record

ArticleCancer cell2021

Molecular subtypes of upper tract urothelial cancer: Setting the stage for precision therapy.

David J McConkey, Nirmish Singla, Phillip Pierorazio, Kara Lombardo, Andres Matoso, Jean Hoffman-Censits

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cancer cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

David J McConkeyUpper Tract Urothelial Cancer Program, Johns Hopkins Greenberg Bladder Cancer Institute and Brady Urological Institute, Baltimore, MD. Electronic address: dmcconk1@jhmi.edu.
Nirmish SinglaUpper Tract Urothelial Cancer Program, Johns Hopkins Greenberg Bladder Cancer Institute and Brady Urological Institute, Baltimore, MD.
Phillip PierorazioUpper Tract Urothelial Cancer Program, Johns Hopkins Greenberg Bladder Cancer Institute and Brady Urological Institute, Baltimore, MD.
Kara LombardoUpper Tract Urothelial Cancer Program, Johns Hopkins Greenberg Bladder Cancer Institute and Brady Urological Institute, Baltimore, MD.
Andres MatosoUpper Tract Urothelial Cancer Program, Johns Hopkins Greenberg Bladder Cancer Institute and Brady Urological Institute, Baltimore, MD.
Jean Hoffman-CensitsUpper Tract Urothelial Cancer Program, Johns Hopkins Greenberg Bladder Cancer Institute and Brady Urological Institute, Baltimore, MD.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A comprehensive genomic characterization of a large, high-quality cohort of upper tract urothelial carcinomas (UTUCs) in this issue of Cancer Cell reveals that UTUCs can be divided into five DNA-based molecular subtypes. Feasibility data establish that molecular subtyping can be performed non-invasively by sequencing tumor DNA in urine.

Indexed as

Carcinoma, Transitional CellUrinary Bladder NeoplasmsDNA, NeoplasmGenomicsHumansUrotheliumDNA, Neoplasm

Identifiers

PMID34129819

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.